PBM PSYENCE BIOMEDICAL LTD. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1985062 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY102.0%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA24.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets8.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.69x
Accruals ratio112.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-03-31 | FY2024*2024-03-31 | FY2023*2023-03-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $342,168 | $954,593 | $1.61M |
| SG&A expense | $1.21M | $557,904 | $366,435 |
| Interest expense | $9,270 | $52,941 | — |
| Pretax income | -$3.66M | -$2.75M | -$3.23M |
| Net income | $1.01M | -$51.16M | -$3.21M |
| EPS (basic) | 5.24 | -4,674.25 | -394.06 |
| EPS (diluted) | 5.24 | -4,674.25 | -394.06 |
| Weighted avg. shares (diluted) | 193,043 | 10,903 | 8,365 |
| Balance sheet | |||
| Cash & equivalents | $6.14M | $733,188 | $1.33M |
| Current assets | $6.56M | $1.13M | $1.59M |
| PP&E, netmay include right-of-use assets (IFRS) | $11,096 | $5,487 | — |
| Total assets | $7.32M | $1.13M | $1.59M |
| Total liabilities | $594,366 | $12.10M | $1.79M |
| Shareholders' equity | $6.72M | -$10.97M | -$200,445 |
| Shares outstanding | — | 178,542 | 0 |
| Cash flow statement | |||
| Operating cash flow | -$3.73M | -$2.95M | -$1.59M |
| Capital expenditure | $9,877 | $5,727 | — |
| Free cash flow | -$3.74M | -$2.95M | — |
| Investing cash flow | -$16,230 | -$5,727 | — |
| Financing cash flow | $9.15M | $2.35M | $1.17M |
| Stock-based compensation | — | $317,882 | $221,287 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.